DRAP Price Delays Leave 40 Drugs Unavailable: Pharma Stocks in Focus

What the DRAP Price Approval Delay Changed for Pharma Makers

Forty medicines have disappeared from pharmacy shelves across Pakistan because the Drug Regulatory Authority of Pakistan, DRAP, has not yet approved new prices for them. When a manufacturer applies to raise the price of a drug and the approval sits pending for months, many companies simply stop supplying that product rather than sell it at a price that no longer covers the cost of raw material, packaging, and distribution. The result is medicines that patients need but cannot buy, and revenue that listed pharma companies are not booking while the standoff continues.

Why Pharma Stocks Are in Focus

Pricing approval delays are a recurring headache for Pakistan's branded pharmaceutical makers, and this is the sharpest sign yet of how big the backlog has become. Abbott Laboratories Pakistan, The Searle Company, Highnoon Laboratories, and AGP Limited all rely on DRAP clearing price increases to keep pace with rising import costs on active pharmaceutical ingredients and the rupee's effect on that import bill. When approvals stall, companies are stuck choosing between selling below cost or pulling a product from the market. Either way, near-term sales suffer.

Which Stocks, and Why

Abbott, an MNC-linked pharma and nutrition maker, imports a large share of its raw material and needs regular price relief to protect margins as the rupee moves. Searle books much of its revenue growth from DRAP price approvals coming through on schedule, so a stuck pipeline of 40 drugs directly slows that growth. Highnoon, with a strong portfolio of domestic brands, and AGP, a branded pharma maker whose revenue depends on steady pricing approvals, face the same bottleneck. None of these companies is named as the maker of the specific 40 drugs in this report, but all four sit in the same regulatory queue, so the disruption is a sector-wide drag rather than a one-off hit to a single name.

What to Watch

The number to track from here is how quickly DRAP clears the backlog and whether the 40 affected drugs return to shelves. A faster clearance would let pharma makers restore supply and book the price increases they have been waiting for, which would be a net positive once it lands. Watch also for any statement from DRAP or industry bodies on a timeline, and for company-level disclosures on which specific products each maker has withdrawn from the market.